Get the Stockscreener App
3.74
5.65%
0.20
Pre-market:
3.81
0.07
+1.87%
Aclaris Therapeutics Inc stock is traded at $3.74, with a volume of 1.18M.
It is up +5.65% in the last 24 hours and up +17.24% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
See More
Previous Close:
$3.54
Open:
$3.61
24h Volume:
1.18M
Relative Volume:
0.56
Market Cap:
$452.87M
Revenue:
$7.83M
Net Income/Loss:
$-64.92M
P/E Ratio:
-7.0606
EPS:
-0.5297
Net Cash Flow:
$-47.22M
1W Performance:
+10.32%
1M Performance:
+17.24%
6M Performance:
+103.26%
1Y Performance:
+139.74%
1-Day Range:
$3.5929
$3.835
1-Week Range:
$3.36
$3.835
52-Week Range:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.74 | 452.87M | 7.83M | -64.92M | -47.22M | -0.5297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics Raises $20 Million in Equity Financing - TipRanks
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - marketscreener.com
Technical Analysis: Why is Aclaris Therapeutics Inc stock going upTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline - Investing.com Canada
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates - Investing.com Australia
Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS) - The Globe and Mail
Aclaris: Q4 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (NASDAQ: ACRS) outlines deep immunology pipeline and 2025 losses - Stock Titan
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - MarketBeat
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Aclaris Therapeutics (ACRS) narrows 2025 loss and details 2026 trial milestones - Stock Titan
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Aclaris Therapeutics Reports Positive Interim Phase 1a Results for ATI-052 and Advances Pipeline with Upcoming Trials and IND Application - Quiver Quantitative
Mouse hair regrows 93% in Aclaris alopecia study, 2025 loss shrinks - Stock Titan
Aclaris: Fourth Quarter Financial Overview - Bitget
Aclaris starts phase 1b trial of ATI-052 in asthma patients - Investing.com Australia
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - The Manila Times
Aclaris tests experimental asthma antibody in new human trial - Stock Titan
Aclaris Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Market Rankings: Whats the beta of Seacoast Banking Corporation of Florida stockJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Will Aclaris Therapeutics Inc. stock recover faster than peersWeekly Market Report & Community Driven Trade Alerts - mfd.ru
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris lines up February spotlight at major biotech investor conferences - MSN
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):